Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
Status:
Completed
Trial end date:
2021-02-07
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety, tolerability and compare the
pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese
subjects who have elevated LDL-C .